In a move to accelerate the integration of artificial intelligence into precision medicine, CellCarta and Imagene AI have announced a significant expansion of their strategic partnership. Building upon an initial collaboration established in July 2026, the two companies are now offering a comprehensive, end-to-end framework designed to assist biopharmaceutical firms in navigating the complex lifecycle of AI-powered biomarker and companion diagnostic (CDx) development.
The expanded collaboration creates a streamlined pipeline that spans the entire developmental spectrum. From initial biomarker strategy and assay development to rigorous validation, clinical trial execution, and ultimate regulatory readiness, the partnership seeks to bridge the gap between algorithmic innovation and clinical utility. By combining CellCarta’s established global laboratory infrastructure and regulatory expertise with Imagene AI’s sophisticated machine learning capabilities, the companies aim to provide a scalable solution for drug developers seeking to bring novel, AI-driven diagnostics to market.
This enhanced synergy is already moving beyond the planning phase, with active programs currently underway for two major global pharmaceutical companies. These projects highlight the tangible potential of the collaboration, focusing on two distinct but complementary areas of pathology. The first is an AI-powered immunohistochemistry (IHC) companion diagnostic development program. The second leverages Imagene AI’s “Lung Prediction Panel,” an innovative tool that identifies key biomarkers for non-small cell lung cancer (NSCLC) directly from standard hematoxylin and eosin (H&E) stained whole-slide images. By enabling these predictions within minutes, the technology offers a practical, time-saving alternative to traditional, more time-consuming diagnostic methods.
For biopharmaceutical companies, the complexity of integrating digital pathology into established clinical trial protocols has historically been a significant barrier. Christopher Ung, Chief Scientific Business Officer at CellCarta, emphasized that success in this arena requires more than just high-performing software.
“Bringing AI-powered approaches into drug development requires more than a strong algorithm,” said Ung. “It requires the ability to validate, deploy, and scale within the rigor of clinical development. Our collaboration with Imagene AI combines their AI pathology capabilities with CellCarta’s laboratory infrastructure, CDx development experience, and regulatory expertise.”
Michael Hreczuck, Senior Vice President of Business Development at Imagene AI, echoed this sentiment, noting that the industry is actively seeking a reliable roadmap for implementation.
“Pharma companies need a practical path for translating AI-powered biomarker and image-analysis capabilities into assays supporting clinical development,” Hreczuck stated. “We are already applying this model across active pharma programs in both AI-powered IHC and H&E-based biomarker prediction.”
By providing a unified solution that addresses the technical, operational, and regulatory challenges of digital diagnostics, CellCarta and Imagene AI are positioning themselves as critical partners in the next generation of biomarker-driven clinical trials. As the partnership deepens, the focus will remain on proving the reliability of AI-driven diagnostic tools, potentially reducing costs and accelerating the time it takes to match the right patients with the right targeted therapies.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
